DSpace Repository

Theranostic Potentials of Gold Nanomaterials in Hematological Malignancies

Show simple item record

dc.contributor.author Shakil, Md Salman
dc.contributor.author Niloy, Mahruba Sultana
dc.contributor.author Mahmud, Kazi Mustafa
dc.contributor.author Kamal, Mohammad Amjad
dc.contributor.author Islam, Md Asiful
dc.date.accessioned 2024-02-11T09:37:51Z
dc.date.available 2024-02-11T09:37:51Z
dc.date.issued 2022-06-21
dc.identifier.issn 2072-6694
dc.identifier.uri http://dspace.daffodilvarsity.edu.bd:8080/handle/123456789/11400
dc.description.abstract Hematological malignancies (HMs) are a heterogeneous group of blood neoplasia generally characterized by abnormal blood-cell production. Detection of HMs-specific molecular biomarkers (e.g., surface antigens, nucleic acid, and proteomic biomarkers) is crucial in determining clinical states and monitoring disease progression. Early diagnosis of HMs, followed by an effective treatment, can remarkably extend overall survival of patients. However, traditional and advanced HMs’ di- agnostic strategies still lack selectivity and sensitivity. More importantly, commercially available chemotherapeutic drugs are losing their efficacy due to adverse effects, and many patients develop resistance against these drugs. To overcome these limitations, the development of novel potent and reliable theranostic agents is urgently needed to diagnose and combat HMs at an early stage. Recently, gold nanomaterials (GNMs) have shown promise in the diagnosis and treatment of HMs. Magnetic resonance and the surface-plasmon-resonance properties of GNMs have made them a suitable candidate in the diagnosis of HMs via magnetic-resonance imaging and colorimetric or electrochemical sensing of cancer-specific biomarkers. Furthermore, GNMs-based photodynamic therapy, photothermal therapy, radiation therapy, and targeted drug delivery enhanced the selectivity and efficacy of anticancer drugs or drug candidates. Therefore, surface-tuned GNMs could be used as sensitive, reliable, and accurate early HMs, metastatic HMs, and MRD-detection tools, as well as selective, potent anticancer agents. However, GNMs may induce endothelial leakage to exacerbate cancer metastasis. Studies using clinical patient samples, patient-derived HMs models, or healthy- animal models could give a precise idea about their theranostic potential as well as biocompatibility. en_US
dc.language.iso en_US en_US
dc.publisher Daffodil International University en_US
dc.subject Hematological oncology en_US
dc.subject Hematologic agents en_US
dc.title Theranostic Potentials of Gold Nanomaterials in Hematological Malignancies en_US
dc.type Article en_US


Files in this item

This item appears in the following Collection(s)

Show simple item record

Search DSpace


Browse

My Account

Statistics